Express Pharma

PDP’s 20 years experience dedicated to clinical research and lifescience logistics

Receives Global BS EN ISO 9001:2008 accreditation to ensure that clients receive the highest levels of service through business practices and operational procedures

PDP is a global specialist courier with over 20 years’ experience dedicated to clinical research and lifescience logistics, cold chain management and pharmaceutical distribution. The global services include export of IMP, clinical trial materials and kits, transport of diagnostic and research specimens, and cold-chain management. PDP has achieved Global BS EN ISO 9001:2008 accreditation to ensure that clients receive the very highest levels of service through our business practices and operational procedures.

PDP employees around the globe are trained in the principles of Good Distribution Practice (GDP) and the operations teams around the world work within and adhere to defined internal and client-specific operating procedures. The core proposition is simple, regardless of value, to deliver your shipment. They are at the right place, at the right time and at the right temperature.

PDP understands that the challenges of daily import and export demands trust and reliability. The company has the experience, capability and best practice procedures in place to respond to and fulfil the requirements every minute of every day.

PDP values and, above all, respects building trust with customers and can demonstrate a proven ability to respond to the specific requirements of clinical trial, lifescience and healthcare logistics on a global scale. It has has successfully built and continues to expand the expertise driven and demanded by our customers in their key markets, geographies and industries.

Industry specialisation inlcudes central laboratory logistics (outbound supplies & inbound specimens), medical and drug R&D, comparator drug & managed access programmes, cord blood, stem cell and bio-banking, public health service and healthcare agencies and pharma/ biopharma.

EP News BureauMumbai

Comments are closed.